Reconfiguring the Cardiovascular Clinical Trial Enterprise in the United States

Population: Cardiovascular disease.

July 23, 2021JAMA Network OpenOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate systemic operational bottlenecks within the United States cardiovascular clinical trial enterprise and propose structural solutions to enhance efficiency, diversity, and evidence quality.
Synthesized operational, regulatory, and infrastructural challenges across the United States cardiovascular clinical research landscape through collaborative multi-stakeholder expert evaluation.
Identified escalating administrative burdens, high development costs, and poor participant representation as primary threats to sustainable cardiovascular evidence generation.
Outlined strategic reforms prioritizing pragmatic trial models, decentralized enrollment mechanisms, digital health technologies, and streamlined regulatory oversight.

P

Population

Cardiovascular disease

Answers are grounded in this paper and cite their sources.

Discusses the reconfiguration of the cardiovascular clinical trial enterprise in the United States.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Deepak L. Bhatt (2021) studied Cardiovascular disease.

View Full Paper

Ask AI

Bookmark

Share